The editors and authors of this supplement were asked to disclose any relationships or financial interests that could be perceived as a potential conflict of interest in the context of their contributions to this supplement. Their disclosures were as follows:
- Louis Kuritzky, MD,
has received honoraria from Pfizer, Eli Lilly, ICOS, Bayer, and GlaxoSmithKline for teaching/speaking or consulting.
- Milton M. Lakin, MD,
has received consulting fees and honoraria from Pfizer and Eli Lilly/ICOS for consulting, teaching/speaking, and advisory board membership. He also reported having stock ownership interest in Pfizer and Eli Lilly.
- Martin M. Miner, MD,
has received a research grant from Auxilium Pharmaceuticals and consulting fees from GlaxoSmithKline/Schering-Plough and Sanofi-Aventis for consulting and serving on speakers’ bureaus.
- Diane K. Newman, RNC, MSN, CRNP,
has received honoraria from Watson Pharmaceuticals, Pfizer, Astellas Pharma, GlaxoSmithKline, Novartis, and SCA Personal Care for teaching/speaking, as well as for serving on an advisory committee (for Watson) and for consulting (for SCA Personal Care).
- Richard E. Payne, MD,
has received honoraria, consulting fees, and an educational grant from Eli Lilly/ICOS for teaching/speaking, consulting, and contracted research; honoraria and consulting fees from Sanofi-Aventis for teaching/speaking and advisory board membership; consulting fees from Boehringer Ingelheim for teaching/speaking and consulting; consulting fees from Pfizer, Johnson & Johnson, and Thomson Healthcare for consulting; and consulting fees from Reliant Pharmaceuticals for serving on an advisory committee. He also reported having an ownership interest in and receiving consulting fees from MedVantx.
- Matt T. Rosenberg, MD,
has received consulting fees and honoraria from Indevus Pharmaceuticals/ESPRIT Pharma, Pfizer, and GlaxoSmithKline for consulting, teaching/speaking, and serving on advisory committees; honoraria and consulting fees from Verathon Medical for consulting and serving on advisory committees; honoraria from Eli Lilly and Auxilium Pharmaceuticals for teaching/speaking; a research grant from Sanofi-Aventis; and consulting fees and honoraria from Ortho-McNeil for consulting and teaching/speaking.
- David R. Staskin, MD,
has received honoraria from ESPRIT Pharma, Novartis, Pfizer, Ortho-McNeil, Watson Pharmaceuticals, and Astellas Pharma for teaching/speaking.
The following authors reported that they have no relationships that could be perceived as a potential conflict of interest in the context of their contributions to this supplement:
- Steven C. Campbell, MD, PhD
- Albert Levy, MD
- Shari A. Page, CFNP
- Jeannette Potts, MD
- Richard Sadovsky, MD
- George P. Samraj, MD
- Andrew J. Stephenson, MD
- Christopher T. Tallman, BS
|
|
